Neuroscience
A report from BusinessWeek from 27 August 2009:
Drug, Biotech Research Spending Hangs Tough
Overall U.S. corporate R&D spending is down 4% since the end of 2007, but some companies have chosen to buck the trend
By Emily Thornton and Frederick Jespersen
[snip]
Corporate America's research spending shrank 4% overall, or $1.9 billion, from the fourth quarter of 2007 through the second quarter of this year, according to data compiled by Capital IQ on 961 U.S. companies. But many health-care companies have boosted their research outlays.
BusinessWeek sought out 25 companies that most aggressively increased their research budgets during the first six months of 2009. Thirteen members of the group, which collectively boosted its spending by $2 billion, were pharmaceutical and biotech companies. Only eight were high-tech outfits, such as Apple (AAPL) and Microsoft (MSFT).
[snip]
Read the full article
- Business World: Biotechnology & Venture Capital
...
- Business World: "the Brain Industry"
From The Seattle Times:Biotech Watch: Biotech companies scramble to develop brain-related products By Steve Johnson Knight Ridder Newspapers The Seattle Times Monday, July 25, 2005 SAN JOSE, Calif. — The prospect of a billion people nearing the age...
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab) And Avonex (interferon Beta-1a)
From: RTE Ireland:Elan releases Tysabri trial figures July 19, 2005 11:09 Pharmaceutical company Elan has released figures showing that its suspended Tysabri drug improved the effectiveness of Biogen's Avonex in the treatment of multiple sclerosis....
- Tysabri (natalizumab): Another Case Of Pml
A third case of progressive multifocal leukoencephalopathy (PML), as reported via The New York Times website: M.S. Drug Tied to a Death Published: March 31, 2005 By Bloomberg News Biogen Idec and the Elan Corporation said that a third patient had developed...
- Business World: Australia's Cogstate
An article from the Australian website, The Age: CogState promotes brain tests to draw takeover offers By Rebecca Urban September 22, 2004 Frustrated by its diminishing value on the Australian sharemarket, diagnostic maker CogState is pitching...
Neuroscience
Business World: R&D Spending
A report from BusinessWeek from 27 August 2009:
Drug, Biotech Research Spending Hangs Tough
Overall U.S. corporate R&D spending is down 4% since the end of 2007, but some companies have chosen to buck the trend
By Emily Thornton and Frederick Jespersen
[snip]
Corporate America's research spending shrank 4% overall, or $1.9 billion, from the fourth quarter of 2007 through the second quarter of this year, according to data compiled by Capital IQ on 961 U.S. companies. But many health-care companies have boosted their research outlays.
BusinessWeek sought out 25 companies that most aggressively increased their research budgets during the first six months of 2009. Thirteen members of the group, which collectively boosted its spending by $2 billion, were pharmaceutical and biotech companies. Only eight were high-tech outfits, such as Apple (AAPL) and Microsoft (MSFT).
[snip]
Read the full article
- Business World: Biotechnology & Venture Capital
...
- Business World: "the Brain Industry"
From The Seattle Times:Biotech Watch: Biotech companies scramble to develop brain-related products By Steve Johnson Knight Ridder Newspapers The Seattle Times Monday, July 25, 2005 SAN JOSE, Calif. — The prospect of a billion people nearing the age...
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab) And Avonex (interferon Beta-1a)
From: RTE Ireland:Elan releases Tysabri trial figures July 19, 2005 11:09 Pharmaceutical company Elan has released figures showing that its suspended Tysabri drug improved the effectiveness of Biogen's Avonex in the treatment of multiple sclerosis....
- Tysabri (natalizumab): Another Case Of Pml
A third case of progressive multifocal leukoencephalopathy (PML), as reported via The New York Times website: M.S. Drug Tied to a Death Published: March 31, 2005 By Bloomberg News Biogen Idec and the Elan Corporation said that a third patient had developed...
- Business World: Australia's Cogstate
An article from the Australian website, The Age: CogState promotes brain tests to draw takeover offers By Rebecca Urban September 22, 2004 Frustrated by its diminishing value on the Australian sharemarket, diagnostic maker CogState is pitching...